Biological Process
| atrial cardiac muscle cell development | | ISS | UniProtKB:P43688 | 2290271 | GO_REF:0000024 | BHF-UCL | GO_REF:0000024 |
| atrial cardiac muscle cell development | | IEA | Ensembl:ENSMUSP00000049898 | 2290271 | GO_REF:0000019 | ENSEMBL | GO_REF:0000019 |
| cell differentiation | | ISS | UniProtKB:P43688 | 2290271 | GO_REF:0000024 | BHF-UCL | GO_REF:0000024 |
| digestive tract development | | ISS | UniProtKB:P43688 | 2290271 | GO_REF:0000024 | BHF-UCL | GO_REF:0000024 |
| digestive tract development | | IEA | Ensembl:ENSMUSP00000049898 | 2290271 | GO_REF:0000019 | ENSEMBL | GO_REF:0000019 |
| embryonic heart tube development | | ISS | UniProtKB:P43688 | 2290271 | GO_REF:0000024 | BHF-UCL | GO_REF:0000024 |
| embryonic heart tube development | | IEA | Ensembl:ENSMUSP00000049898 | 2290271 | GO_REF:0000019 | ENSEMBL | GO_REF:0000019 |
| embryonic heart tube development | | IMP | | 2290271 | PMID:15649947 | HGNC | PMID:15649947 |
| hypothalamus development | | ISS | UniProtKB:P43688 | 2290271 | GO_REF:0000024 | BHF-UCL | GO_REF:0000024 |
| hypothalamus development | | IEA | Ensembl:ENSMUSP00000049898 | 2290271 | GO_REF:0000019 | ENSEMBL | GO_REF:0000019 |
| negative regulation of apoptotic process | | ISS | UniProtKB:P43688 | 2290271 | GO_REF:0000024 | BHF-UCL | GO_REF:0000024 |
| negative regulation of apoptotic process | | IEA | Ensembl:ENSMUSP00000049898 | 2290271 | GO_REF:0000019 | ENSEMBL | GO_REF:0000019 |
| pericardium development | | ISS | UniProtKB:P43688 | 2290271 | GO_REF:0000024 | BHF-UCL | GO_REF:0000024 |
| pericardium development | | IEA | Ensembl:ENSMUSP00000049898 | 2290271 | GO_REF:0000019 | ENSEMBL | GO_REF:0000019 |
| pharyngeal system development | | ISS | UniProtKB:P43688 | 2290271 | GO_REF:0000024 | BHF-UCL | GO_REF:0000024 |
| pharyngeal system development | | IEA | Ensembl:ENSMUSP00000049898 | 2290271 | GO_REF:0000019 | ENSEMBL | GO_REF:0000019 |
| positive regulation of cell proliferation | | ISS | UniProtKB:P43688 | 2290271 | GO_REF:0000024 | BHF-UCL | GO_REF:0000024 |
| positive regulation of cell proliferation | | IEA | Ensembl:ENSMUSP00000049898 | 2290271 | GO_REF:0000019 | ENSEMBL | GO_REF:0000019 |
| tongue development | | ISS | UniProtKB:P43688 | 2290271 | GO_REF:0000024 | BHF-UCL | GO_REF:0000024 |
| tongue development | | IEA | Ensembl:ENSMUSP00000049898 | 2290271 | GO_REF:0000019 | ENSEMBL | GO_REF:0000019 |
| transcription, DNA-dependent | | IDA | | 2290271 | PMID:15649947 | HGNC | PMID:15649947 |
| ventricular cardiac muscle cell development | | ISS | UniProtKB:P43688 | 2290271 | GO_REF:0000024 | BHF-UCL | GO_REF:0000024 |
| ventricular cardiac muscle cell development | | IEA | Ensembl:ENSMUSP00000049898 | 2290271 | GO_REF:0000019 | ENSEMBL | GO_REF:0000019 |
Cellular Component
| nucleus | | IC | GO:0003700 | 2290271 | PMID:15649947 | HGNC | PMID:15649947 |
| nucleus | | IEA | UniProtKB-SubCell:SL-0191 | 2290271 | GO_REF:0000040 | UniProtKB | GO_REF:0000040 |
Molecular Function
| sequence-specific DNA binding | | IEA | InterPro:IPR001356|InterPro:IPR017970 | 2290271 | GO_REF:0000002 | InterPro | GO_REF:0000002 |
| sequence-specific DNA binding transcription factor activity | | IDA | | 2290271 | PMID:15649947 | HGNC | PMID:15649947 |
| sequence-specific DNA binding transcription factor activity | | IEA | InterPro:IPR001356 | 2290271 | GO_REF:0000002 | InterPro | GO_REF:0000002 |
| 2314746 | GLUCO80_H | Glucose level QTL 80 (human) | .78 | .005 | Glucose level | non-insulin dependent | 8 | 1 | 25742237 | Human |
| 1643413 | BW270_H | Body Weight QTL 270 (human) | 1.96 | .0013 | Body weight | | 8 | 1 | 25836028 | Human |
| 2293372 | PRSTS238_H | Prostate tumor susceptibility QTL 238 (human) | | .03 | Prostate tumor susceptibility | | 4 | 1 | 25836028 | Human |
| 2293375 | PRSTS237_H | Prostate tumor susceptibility QTL 237 (human) | | .026 | Prostate tumor susceptibility | | 8 | 1 | 25836028 | Human |
| 2314716 | INSUL17_H | Insulin level QTL 17 (human) | 2.29 | .106 | Insulin level | | 8 | 1 | 25836028 | Human |
| 2314791 | BW512_H | Body weight QTL 512 (human) | 2.68 | | Body fat amount | abdominal | 8 | 1 | 25836028 | Human |
| 2289455 | BW300_H | Body weight QTL 300 (human) | 2.34 | | Body weight | body mass index | 8 | 252539 | 26252539 | Human |
| 2302771 | MAMTS2_H | Mammary tumor susceptibility QTL 2 (human) | 2.41 | | Mammary tumor susceptibility | | 8 | 1348312 | 27348312 | Human |
| 2293393 | PRSTS281_H | Prostate tumor susceptibility QTL 281 (human) | | | Prostate tumor susceptibility | | 8 | 1818436 | 27818436 | Human |
| 2293425 | PRSTS279_H | Prostate tumor susceptibility QTL 279 (human) | | | Prostate tumor susceptibility | | 8 | 1818436 | 27818436 | Human |
| 2293436 | PRSTS263_H | Prostate tumor susceptibility QTL 263 (human) | | | Prostate tumor susceptibility | | 8 | 1818436 | 27818436 | Human |
| 2293446 | PRSTS261_H | Prostate tumor susceptibility QTL 261 (human) | | | Prostate tumor susceptibility | | 8 | 1818436 | 27818436 | Human |
| 2293453 | PRSTS262_H | Prostate tumor susceptibility QTL 262 (human) | | | Prostate tumor susceptibility | | 8 | 1818436 | 27818436 | Human |
| 1358847 | MULTSCL28_H | Multiple sclerosis susceptibility QTL 28 (human) | 1.2 | | Multiple sclerosis susceptibility | | 8 | 2130333 | 59708448 | Human |
| 2314771 | GLUCO108_H | Glucose level QTL 108 (human) | 1.77 | | Glucose level | non-insulin dependent | 8 | 2649722 | 28649722 | Human |
| 2289414 | BW405_H | Body weight QTL 405 (human) | 1.95 | .014 | Body fat amount | none | 8 | 2649722 | 28649722 | Human |
| 2301805 | PRSTS432_H | Prostate tumor susceptibility QTL 432 (human) | | .005 | Prostate tumor susceptibility | | 8 | 3065621 | 29065621 | Human |
| 2289210 | BW354_H | Body weight QTL 354 (human) | | .0246 | Body fat amount | percent fat | 8 | 4826267 | 30826267 | Human |
| 1298459 | BP19_H | Blood pressure QTL 19 (human) | .0284 | | Blood pressure | hypertension susceptibility | 8 | 5352662 | 31352662 | Human |
| 1643563 | GLUCO26_H | Glucose level QTL 26 (human) | .73 | .033 | Glucose level | non-insulin-dependent | 8 | 6175933 | 32175933 | Human |
| 1298482 | BP2_H | Blood pressure QTL 2 (human) | 1.8 | | Blood pressure | diastolic | 8 | 6810676 | 32810676 | Human |
| 2302780 | MAMTS3_H | Mammary tumor susceptibility QTL 3 (human) | 2.51 | | Mammary tumor susceptibility | | 8 | 7061906 | 33061906 | Human |
| 2315821 | GLUCO181_H | Glucose level QTL 181 (human) | 1.68 | | Glucose level | | 8 | 7367296 | 33367296 | Human |
| 2289549 | BW429_H | Body weight QTL 429 (human) | | | Body weight | BMI | 8 | 8414972 | 34414972 | Human |
| 1643088 | BW154_H | Body weight QTL 154 (human) | | .0239 | Body fat amount | percent body fat | 8 | 8602049 | 34602049 | Human |
| 1643079 | BW118_H | Body Weight QTL 118 (human) | 2.39 | .000046 | Body weight | | 8 | 9433429 | 35433429 | Human |
| 2315064 | GLUCO136_H | Glucose level QTL 136 (human) | 1.348 | | Glucose level | | 8 | 9433429 | 35433429 | Human |
| 2292929 | PRSTS132_H | Prostate tumor susceptibility QTL 132 (human) | 1.72 | | Prostate tumor susceptibility | | 8 | 12441347 | 38441347 | Human |
| 2292935 | PRSTS187_H | Prostate tumor susceptibility QTL 187 (human) | 5.75 | .0079 | Prostate tumor susceptibility | | 8 | 12441347 | 38441347 | Human |
| 2292874 | PRSTS82_H | Prostate tumor susceptibility QTL 82 (human) | | | Prostate tumor susceptibility | | 8 | 13811912 | 39811912 | Human |
| 2289593 | BW469_H | Body weight QTL 469 (human) | 1.6 | | Body morphometry | waist to hip ratio | 8 | 21451041 | 47451041 | Human |
| 1558703 | SCL6_H | Serum cholesterol level QTL 1 (human) | 1.2 | | Lipid level | HDL cholesterol | 8 | 22433395 | 38326352 | Human |